Findings from the 16th wave of Spherix Global Insights’ COVID-19 research indicate that telemedicine is firmly entrenched, industry interaction remains...
According to Spherix Global Insights, specialists in dermatology, gastroenterology, nephrology, neurology, and rheumatology have little interest in engaging with industry,...
According to Spherix Global Insight’s COVID-19 tracker, dermatologists and rheumatologists alike report that they are more inclined to use Otezla...
Gastroenterologists continue to feel the resonating effects of the COVID-19 pandemic as they work to return operations to pre-pandemic levels,...
Though surveyed US specialists report shrinking trepidation prescribing certain drugs amid the COVID-19 pandemic, hesitation to prescribe new brands remains...
According to Spherix Global Insights, just one-tenth of specialty physician offices are operating at normal capacity, and doctors report facing...
According to feedback from the sixth wave of COVID-19 impact tracking, Spherix Global Insights finds that patient volumes remain severely...
Use in treatment-naïve patients drives recent growth of Biogen’s Tecfidera and Genzyme’s Aubagio in Canada, as reported switch share has...
EXTON, Pa., April 20, 2020 /PRNewswire/ ― Spherix Global Insights, the leading independent market intelligence firm in specialty biopharma markets,...
The impact to practices has been severely disruptive, taking a devastating personal and financial toll on specialty physicians according to...
From: FiercePharma By: Angus Liu COVID-19 is Bad News for New Drug Launches. Which Will Suffer Most? A recent survey...
Looking to the future, the approval of the first dual-therapy migraine label would make Nurtec a substantial competitive threat on...
